

# Comprehensive Tumor Profiling




## Comprehensive Profiling Based On the Analysis of Tumor Tissue

The changing paradigm – away from a one-size-fits-all approach towards precision medicine – raises the importance of comprehensive genomic profiling of tumor samples.

Comprehensive genomic tumor profiling refers to the simultaneous evaluation of several biomarkers within one analysis. This approach not only enables detecting the most relevant predictive markers for current targeted therapies but also key immunology biomarkers, such as the tumor mutational burden (TMB) and the microsatellite instability (MSI). TMB is a biomarker that measures the number of somatic mutations present in a cancer patient's tumor and is quantified as mutations per megabase (mut/Mb). Another key immunotherapy biomarker is the MSI, which is caused by the failure of the DNA mismatch repair system.

The application areas of comprehensive tumor profiling are manifold, with a focus on:

- ✗ Stratifying patients for the best treatment choice
- ✗ Identifying patients eligible for clinical trials
- ✗ Driving clinical research, especially in the area of immune therapy



## Explore Our Product Portfolio for Comprehensive Tumor Profiling

	CTP Somatic	CTP Tumor	CTP TUM Panel	CTP PAT Panel	CTP FUS Panel
<b>Species</b>	Human				
<b>Sequencing panel</b>	Whole Exome Sequencing (Twist Bioscience)		Somatic Tumor Panel (CeGaT GmbH)	Molecular Pathology Panel (CeGaT GmbH)	RNA Fusion Panel (CeGaT GmbH)
<b>Number of analyzed genes</b>	~ 20,000		~ 760	55	160
<b>Analysis of tumor and normal tissue</b>	Yes	No	Yes	No	No
<b>Starting material</b>	Fresh frozen tissue, FFPE tissue, high molecular weight DNA, or fragmented DNA (FFPE)				Isolated RNA
<b>Sequencing platform</b>	Illumina				
<b>Output</b>	12 Gb normal sample 18 Gb tumor sample	12 Gb or 24 Gb (dependent on the tumor content)	10 Gb	Flexible	Flexible
<b>Included deliverables</b>	Project report & FASTQ files				

Want to Discover More?  
 We invite you to take a look at our website.  
[www.cegat.com/comprehensive-tumor-profiling](https://www.cegat.com/comprehensive-tumor-profiling)





## About Us

CeGaT was founded in 2009 in Tübingen, Germany. Our scientists are specialized in next-generation sequencing (NGS) for genetic diagnostics, and we also provide a variety of sequencing services for research purposes and pharma solutions. Our sequencing service portfolio is complemented by analyses suited for microbiome, immunology, and translational oncology studies.

Our dedicated project management team of scientists and bio-informaticians works closely with you to develop the best strategy to realize your project. Depending on its scope, we select the most suitable library preparation and conditions on our sequencing platforms.

**We would be pleased to provide you with our excellent service.  
Contact us today to start planning your next project.**



Accredited by DAKKS according to  
DIN EN ISO/IEC 17025:2018



CLIA CERTIFIED ID: 99D2130225

CeGaT GmbH  
Research & Pharma Solutions  
Paul-Ehrlich-Str. 23  
72076 Tübingen  
Germany

Phone: +49 7071 56544-333

Fax: +49 7071 56544-56

Email: [rps@cegat.com](mailto:rps@cegat.com)

Web: [www.cegat.com/rps](http://www.cegat.com/rps)